120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
长效 GLP-1 受体激动剂在 2 型糖尿病管理中的临床综合评价
Authors Chen Q, Chen T , Lin W , Chen X
Received 30 November 2025
Accepted for publication 28 January 2026
Published 10 February 2026 Volume 2026:19 585436
DOI https://doi.org/10.2147/DMSO.S585436
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Halis Akturk
Qiying Chen,1,* Tianyu Chen,2,* Weicheng Lin,1,* Xi Chen1
1Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, 362000, People’s Republic of China; 2Department of Nursing, Quanzhou Medical College, Quanzhou, Fujian, 362011, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Weicheng Lin, Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, 362000, People’s Republic of China, Email weichenglin96@163.com
Objective: To conduct a systematic, multi-dimensional clinical evaluation of five long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) available in China, providing evidence-based guidance for clinical preference and institutional formulary selection.
Methods: This study was structured according to the “A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions. (Second Edition)” and the “Guidelines for the Workflow of Clinical Comprehensive Evaluation of Drugs” We constructed a quantitative evaluation system encompassing six core dimensions: efficacy, safety, economy, innovation, suitability, and accessibility. Indicator weights were determined via a Delphi expert consultation process. Dulaglutide, semaglutide, polyethylene glycol loxenatide, tirzepatide, and mazdutide were evaluated using a 100-point scoring system based on drug labels, systematic literature review, and real-world data.
Results: The comprehensive scores were as follows: semaglutide (76.6), dulaglutide (72.6), polyethylene glycol loxenatide (64.8), tirzepatide (62.9), and mazdutide (55.1). Semaglutide and dulaglutide, classified as Strong Recommendations, demonstrated superior efficacy (particularly in cardio-renal protection) and overall value. Tirzepatide and polyethylene glycol loxenatide were Conditionally Recommended; the former shows outstanding potential for glycaemic control and weight loss but is limited by cost, while the latter offers advantages in accessibility and economy but lacks high-level cardiovascular outcome evidence. Mazdutide is Not Recommended currently due to insufficient evidence, absence from the national reimbursement drug list, and high cost.
Conclusion: This evaluation identifies semaglutide and dulaglutide as the preferred long-acting GLP-1RAs in China’s current therapeutic landscape. The standardized, transparent six-dimensional framework provides a replicable methodology for the comprehensive assessment of chronic disease therapies, supporting rational drug selection and resource allocation.
Keywords: type 2 diabetes, GLP-1 receptor agonists, long-acting formulations, clinical comprehensive evaluation, multi-criteria decision analysis
1Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, 362000, People’s Republic of China; 2Department of Nursing, Quanzhou Medical College, Quanzhou, Fujian, 362011, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Weicheng Lin, Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, 362000, People’s Republic of China, Email weichenglin96@163.com
Objective: To conduct a systematic, multi-dimensional clinical evaluation of five long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) available in China, providing evidence-based guidance for clinical preference and institutional formulary selection.
Methods: This study was structured according to the “A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions. (Second Edition)” and the “Guidelines for the Workflow of Clinical Comprehensive Evaluation of Drugs” We constructed a quantitative evaluation system encompassing six core dimensions: efficacy, safety, economy, innovation, suitability, and accessibility. Indicator weights were determined via a Delphi expert consultation process. Dulaglutide, semaglutide, polyethylene glycol loxenatide, tirzepatide, and mazdutide were evaluated using a 100-point scoring system based on drug labels, systematic literature review, and real-world data.
Results: The comprehensive scores were as follows: semaglutide (76.6), dulaglutide (72.6), polyethylene glycol loxenatide (64.8), tirzepatide (62.9), and mazdutide (55.1). Semaglutide and dulaglutide, classified as Strong Recommendations, demonstrated superior efficacy (particularly in cardio-renal protection) and overall value. Tirzepatide and polyethylene glycol loxenatide were Conditionally Recommended; the former shows outstanding potential for glycaemic control and weight loss but is limited by cost, while the latter offers advantages in accessibility and economy but lacks high-level cardiovascular outcome evidence. Mazdutide is Not Recommended currently due to insufficient evidence, absence from the national reimbursement drug list, and high cost.
Conclusion: This evaluation identifies semaglutide and dulaglutide as the preferred long-acting GLP-1RAs in China’s current therapeutic landscape. The standardized, transparent six-dimensional framework provides a replicable methodology for the comprehensive assessment of chronic disease therapies, supporting rational drug selection and resource allocation.
Keywords: type 2 diabetes, GLP-1 receptor agonists, long-acting formulations, clinical comprehensive evaluation, multi-criteria decision analysis